Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T16:21:16.928Z.
Calculation as of: 2026-10-06T16:21:16.928Z.
Quote observation: 2026-10-06T16:20:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a39ca6935a26d8aa5af55aa8ea7db8fcfa7d32011c972ec9cce8dd9481767f6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
BridgeBio Oncology Therapeutics Inc.
Market Cap
$287.88M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$288.21M
EV/Sales Ratio
9.87x
TTM Avg
250.43x
3Y Avg
190.32x
5Y Avg
110.72x
Market Cap
$288.33M
EV/Sales Ratio
N/A
TTM Avg
19.43x
3Y Avg
19.05x
5Y Avg
19.05x
Market Cap
$286.63M
EV/Sales Ratio
0.53x
TTM Avg
2.42x
3Y Avg
2.68x
5Y Avg
2.39x
Market Cap
$283.38M
EV/Sales Ratio
N/A
TTM Avg
5.51x
3Y Avg
58.44x
5Y Avg
51.98x
Market Cap
$283.11M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$295.55M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$278.73M
EV/Sales Ratio
1.01x
TTM Avg
0.84x
3Y Avg
0.87x
5Y Avg
1.56x
Market Cap
$278.40M
EV/Sales Ratio
N/A
TTM Avg
828.82x
3Y Avg
299.34x
5Y Avg
212.23x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $287.88M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.21M | 9.87x | 250.43x | 190.32x | 110.72x |
| Sagimet Biosciences Inc. (SGMT)vs › | $288.33M | N/A | 19.43x | 19.05x | 19.05x |
| Standard BioTools Inc. (LAB)vs › | $286.63M | 0.53x | 2.42x | 2.68x | 2.39x |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.38M | N/A | 5.51x | 58.44x | 51.98x |
| Indaptus Therapeutics, Inc. (INDP)vs › | $283.11M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $295.55M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $278.73M | 1.01x | 0.84x | 0.87x | 1.56x |
| SAB Biotherapeutics, Inc. (SABS)vs › | $278.40M | N/A | 828.82x | 299.34x | 212.23x |
| Fate Therapeutics, Inc. (FATE)vs › | $276.62M | 49.28x | 36.37x | 26.31x | 30.77x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
